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http://dx.doi.org/10.1016/j.jmii.2013Background: Autoimmune diseases-related arthritis has been rarely reported in HIV-1-infected
patients. We aimed to investigate the incidence and clinical manifestations of autoimmune
diseases-related arthritis in HIV-infected patients in the era of highly active antiretroviral ther-
apy (HAART) in Taiwan.
Methods: We retrospectively reviewed medical records of all HIV-infected patients who had a
diagnosis of autoimmune arthritis between 1993 and 2013. Demographic characteristics, clin-
ical manifestations, serial CD4 and CD8 lymphocyte counts and plasma HIV viral loads, HLA-B27
status, and treatment response to HIV and rheumatic diseases were recorded.
Results: During the 20-year study period, totally 26 HIV-infected patients with autoimmune
arthritis (0.7%) were diagnosed among 3623 HIV-infected patients. There were 18 patients with
ankylosing spondylitis (AS), six with rheumatoid arthritis (RA), one with psoriatic arthritis, and
one with Sjo¨gren’s syndrome. HLA-B27 antigens were all detected positive of AS patients.
Fifteen patients (57.7%) developed autoimmune arthritis after HAART was initiated. The me-
dian age and CD4þ T lymphocyte counts at the diagnosis of autoimmune arthritis were 35
(20e62 years) and 406 (3e695 cells/mL), respectively. Three patients had typical presentations
of Reiter’s syndrome. Both AS and RA patients achieved a good virological response with unde-
tectable plasma HIV RNA load 12 months after receiving HAART(85.71% vs. 80%, respectively,
p Z 0.999). The treatment response to antirheumatic medications were similar between AS
patients and RA patients (77.8% vs. 50%, p Z 0.3068), but seems to be better than that re-
ported for the general population (30e40%).
Conclusion: A low prevalence of autoimmune arthritis among HIV-infected patients in the era
of HAART was similar to that of the general Taiwanese population. Clinical manifestations ofof Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, Taiwan.
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Autoimmune arthritis and HIV infection 131HIV-infected patients were similar to those described in HIV-uninfected patients. However, the
treatment response to antirheumatic agents was better in HIV-infected patients in our study.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Autoimmune arthritis occurred with a wide spectrum
among HIV-infected patients.1 In the Taiwanese general
population, rheumatoid arthritis (RA) and ankylosing spon-
dylitis (AS) were the most two common types of autoim-
mune arthritis, with the prevalence of 0.26e0.93% and
0.19e0.54%, respectively.2 AS occurs more commonly in
men than women, and its incidence is about 0.52% in the
United States.3 The probable pathogenic mechanism of RA
involves various types of cytokines, such as transforming
growth factor (TGF) and interleukins (ILs), and elicits cos-
timulation of dendritic cells, B cells, and T cells.4 In the era
of highly active antiretroviral therapy (HAART), worsening
of RA with antiretroviral therapy had been observed, and it
may reveal a pivotal role of CD4þ T lymphocytes in the
pathogenesis of RA.5 The precise pathogenesis of AS re-
mains unknown, although its pathogenic mechanism in the
arthritic damage may be associated with HLA-B27-related
antigen presentation of arthritogenic peptides and the
involvement of immune effector cells that include CD4þ/
CD8þ T lymphocytes, and natural killer cells.6 The HLA-B27
allele that has been shown to be associated with slower
progression of HIV infection is highly correlated with the
development of AS.7,8 Increasing percentage of CD4þ/
CCR4þ T cells is found among patients with AS.9 Psoriatic
arthritis (PsA), Sjo¨gren’s syndrome, and systemic lupus er-
ythematosus (SLE) could also be found in HIV-infected
patients.10,11
With the initiation of HAART, CD4þ T lymphocyte counts
increase significantly in HIV-infected patients. Increased
inflammatory responses, also termed immune reconstitu-
tion inflammatory syndrome have been widely reported in
HIV-infected patients with opportunistic infections when
combination antiretroviral therapy is concurrently initi-
ated.12 Therefore, immune reconstitution after HAART may
increase the risk for autoimmune arthritis. In this study, we
aimed to know the prevalence of autoimmune diseases-
related arthritis and describe the clinical manifestations
of autoimmune arthritis in HIV-infected patients in Taiwan,
where HIV infections occur predominantly in men (male-to-
female ratio: 13.38).8Materials and methods
Study population
We identified patients with HIV infection (ICD-9-CM code
V08, 042) by using our computer-based international clas-
sification of disease (ICD) code database at the National
Taiwan University Hospital (NTUH) between 1993 and 2013.
We further identified HIV-infected patients with AS (ICD-9-CM code 720.0), RA (ICD-9-CM code 714.0), SLE (ICD-9-CM
code 710.0), PsA (ICD-9-CM code 696.1), and Sjo¨gren’s
syndrome (ICD-9-CM code 710.2). We then retrospectively
reviewed the medical records of the HIV-infected patients
with autoimmune diseases-related arthritis who sought
medical attention at NTUH. The diagnosis of AS was made
by according to the modified New York criteria.13 The
criteria include one of the three symptomatic presentations
(low back pain or stiffness, limitation of motion of the
lumbar spine in the sagittal and frontal planes, and limi-
tation of chest expansion relative to normal values corre-
lated for age and sex), and radiographic evidence of
sacroileitis. If both symptomatic and radiographic criteria
are fulfilled, he or she will be classified as being a definite
case of AS. The diagnosis of RA was based on the criteria set
by American College of Rheumatology (ACR) Board of Di-
rectors and the European League Against Rheumatism
(EULAR) Executive Committee.14 RA diagnosis requires
clinical scoring for more than six points (full score: 10
points).
We used a standardized case record form to collect in-
formation on demographic characteristics, smoking status,
alcohol consumption, comorbidities, concomitant medica-
tions, opportunistic infections during the HIV disease
course, and antiretroviral regimens. We also recorded
associated extra-articular manifestations, CD4 and CD8
lymphocyte counts, and plasma HIV RNA loads before and
after the start of HAART, clinical response to antirheumatic
regimens, serum creatinine value, liver function profiles,
viral hepatitis coinfection, Rapid plasma reagin titer,
autoimmune profiles (antinuclear antibody, rheumatoid
factor, C3, C4, IgG, IgA, IgM, or other autoimmune anti-
bodies), and HLA-B27 status. The treatment response was
defined as good symptomatic control with no pain after 12
month’s follow-up.
Laboratory investigations
HLA-B27 was detected by flow cytometry for leukocyte
surface markers. Plasma HIV RNA load was quantified using
the COBAS AMPLICOR HIV-1 MONITOR test (v1.5, Roche Di-
agnostics Corporation, IN) with a lower detection limit of 40
copies/mL, and the CD4 lymphocyte count was determined
using FACFlow (BD FACSCalibur, Becton Dickinson, CA).
The study was approved by the Research Ethics Com-
mittee of the hospital (Registration no. 201212177RINB) and
written or oral informed consent was waived.
Statistical analysis
The CochraneArmitage Test for Trend was performed to
analyze the prevalence of autoimmune arthritis among
the different time periods. We used Fisher’s exact test or
132 J.-J. Yang et al.Chi-squared test for categorical variables among the two
groups of patients (AS and RA), and utilized the Wilcoxon
test for the examination of continuous variables. A p value
<0.05 was considered statistically significant. The confi-
dence interval was set at 95%. The analysis was conducted
using the statistical package SAS 9.3 (SAS Institute Inc.,
Cary, NC, USA).Table 1 Overall clinical characteristics of the 26 HIV-
infected patients with autoimmune arthritis
Characteristics Autoimmune arthritis
(n Z 26)
Age at the diagnosis of
autoimmune arthritis, y
35 (20e62)
Male, sex 24 (92.3)
Body weight, kg 62 (47e92)
HIV risk factors
Homosexual 20 (76.9)
Heterosexual 2 (7.69)
Bisexual 1 (3.85)
IDU 3 (11.5)
Cigarette smoking 13 (50)
Alcohol consumption 5 (19.2)
Comorbidities
Diabetes mellitus 1 (3.85)
Figure 2. The prevalence of autoimmune arthritis among
HIV-infected patients (category by calendar years) (trend
analysis, p Z 0.391).Results
During the 20-year study period, 3623 HIV-infected patients
had sought HIV care at the hospital at least once; 26 pa-
tients had a diagnosis of autoimmune diseases-related
arthritis. There were 18 patients with AS (0.49%), six with
RA (0.16%), one with PsA (0.03%), and one with primary
Sjo¨gren’s syndrome (0.03%). The prevalence of autoimmune
arthritis by different disease categories is shown in Fig. 1,
and the prevalence among the general Taiwanese popula-
tion is also revealed. The prevalence of autoimmune
arthritis within different time periods is shown in Fig. 2.
The trend of prevalence changes was not statistically
significantly associated with pre-HAART, early-HAART, and
late-HAART (p Z 0.391).
The overall clinical characteristics of the 26 HIV-infected
patients with autoimmune arthritis are shown in Table 1.
The median age was 35 years at the diagnosis of autoim-
mune arthritis. The median CD4 T lymphocyte counts was
205 cells/mL at the diagnosis of HIV infection, and 81.8% of
these achieved an undetectable plasma HIV viral load 12
months after taking HAART.
We compare with two most common autoimmune
arthritis, AS versus RA. The clinical characteristics of the 18
HIV-infected patients with AS and six with RA are shown in
Table 2. The patients who received the diagnosis of RA had
a higher median age at the diagnosis of autoimmune
arthritis (46 vs. 34; p Z 0.018). The AS group had a signif-
icantly higher proportion of patients carrying HLA-B27
alleles (100% vs. 0%, p Z 0.0022). There were no other
statistically significant differences in the proportion ofChronic lung disease 2 (7.69)
Chronic hepatitis B 4 (15.4)
Chronic hepatitis C 4 (15.4)
CD4 count at diagnosis of HIV 205 (0.5e763)
[N Z 23]
CD8 count at diagnosis of HIV 754 (78e2392)
[N Z 19]
CD4 count change 12 mo after
initiating HAART
þ175 (14e578)
[N Z 22]
Plasma HIV RNA load at the
diagnosis of HIV, log10
copies/mL
5.39 (3.77e6.75)
[N Z 21]
Achieved undetectable plasma
HIV load 12 mo after
initiation of HAART
18 (81.8) [N Z 22]
Autoimmune arthritis
diagnosed after HAART
15 (57.7)
Data represent the median value (total range) for continuous
variables and the number of cases (%) for categorical variables.
N indicates the number of patients being tested.
IDU Z intravenous drug abuser.
Figure 1. The prevalence of autoimmune arthritis among
HIV-infected patients (category by diseases) compared to the
general Taiwanese population.2 AS Z ankylosing spondylitis;
NA Z not available; PsA Z psoriatic arthritis;
RA Z rheumatoid arthritis.
Table 2 Clinical characteristics of the 24 HIV-infected patients with AS and RA
Characteristics AS
(n Z 18)
RA
(n Z 6)
p
Age, y 34 (20e44) 46 (23e62) 0.018
Male sex 18 (100) 5 (83.3) 0.250
Body weight, kg 63.5 (47e85) 59 (50e92) 0.685
HIV risk factors
Homosexual 15 (88.3) 4 (66.7) 0.568
Heterosexual 1 (5.6) 1 (16.7) 0.446
Bisexual 1 (5.6) 0 (0) 0.999
IDU 1 (5.6) 1 (16.7) 0.446
Cigarette smoking 8 (44.4) 3 (50) 0.999
Alcohol use 3 (16.7) 2 (33.3) 0.568
Underlying medical diseases
Diabetes mellitus 0 (0) 1 (16.7) 0.250
Chronic lung disease 0 (0) 2 (33.3) 0.054
Chronic hepatitis B 2 (11.7) 1 (16.7) 0.999
Chronic hepatitis C 2 (11.7) 1 (16.7) 0.999
Patients who had OIs during the course of HIV infection 4 (22.2) 3 (50) 0.307
Pneumocystosis 1 (5.6) 1 (16.7) 0.446
CMV disease 2 (11.1) 1 (16.7) 0.999
MAC infection 2 (11.1) 1 (16.7) 0.999
Tuberculosis 0 (0) 1 (16.7) 0.250
Kaposi sarcoma 1 (5.6) 0 (0) 0.999
Extra-articular manifestations 6 (33.3) 0 (0) 0.277
Psoriasis 1 (5.56) 0 (0) 0.999
Uveitis 4 (16.7) 0 (0) 0.539
Ulcerative colitis 1 (5.56) 0 (0) 0.999
HLA-B27(þ) status 12 (100) [N Z 12] 0 (0) [N Z 3] 0.002
Laboratory data at the diagnosis of autoimmune arthritis
Elevated ANA titer 3 (60) [N Z 5] 1 (20) [N Z 5] 0.524
RF titer (U/mL) 0 (0e27.8) [N Z 4] 0 (0e30.9) 0.999
CRP level (mg/dL) 2.68 (0.08e14.74) [N Z 13] 1.05 (0.04e4.21) 0.125
ESR level (mm) 67.6 (9e120) [N Z 11] 34.3 (1e93) 0.159
Data represent the median value (total range) for continuous variables and the number of cases (%) for categorical variables. N indicates
the number of patients being tested.
ANA Z antinuclear antibody; AS Z ankylosing spondylitis; CMV Z cytomegalovirus; CRP Z C reactive protein; ESR Z erythrocyte
sedimentation rate; IDU Z intravenous drug abuser; MAC Z Mycobacterium avium-intracellulare complex; OIs Z opportunistic in-
fections; RA Z rheumatoid arthritis; RF Z rheumatoid factor.
Autoimmune arthritis and HIV infection 133males, HIV infection risk factors, baseline medical comor-
bidities, and opportunistic infections during the HIV disease
course, and the C reactive protein (CRP) and erythrocyte
sedimentation rate (ESR) levels at the diagnosis of auto-
immune arthritis. Six of the AS patients had extra-articular
manifestations, but none of the RA patients had extra-
articular involvement (Table 1). Three of the AS patients
also fulfilled the criteria of Reiter’s syndrome (arthritis and
uveitis). One had concurrent co-infection of syphilis (VDRL
titer 1:1024). The other had biopsy-proven ulcerative coli-
tis. All the three patients with Reiter’s syndrome improved
after the anti-HIV treatment. All the clinical presentations
of Reiter’s syndrome may be due to the presentations of
HIV-related arthritis.
In two patients of the AS group, the diagnosis of HIV
infection and AS were made at the same time; and in seven
AS patients (50%) and one RA patient (16.7%), the diagnosis
of autoimmune arthritis was made before using HAART.
Only one patient of the AS group had aggravating arthritissymptoms after initiating HAART, and needed to add Pla-
quenil for better symptomatic control.
The virological response, CD4þ/CD8þ T lymphocyte
counts at the initiation of HAART, and change of CD4þ/
CD8þ T lymphocyte counts 12 months after the initiation of
HAART are shown in Table 2. There were no statistically
significant differences between the AS and RA groups.
About 80% of both two groups achieved undetectable
plasma HIV RNA load. The median CD4þ T lymphocyte in-
creases at 12 months after the initiation of HAARTwere 175
and 168 cells/mL, respectively (p Z 0.668).
Nine of the AS patients (50%) and five of the RA patients
(83.3%) received the diagnosis of autoimmune arthritis
after initiating HAART. The time interval from the initiation
of HAART to the diagnosis of AS and RA ranged from 1 month
to 46 months, and 8 months to 144 months, respectively.
At the start of combination antiretroviral therapy, none of
the 14 patients had symptoms and signs suggestive of
autoimmune arthritis, such as low back pain, knee pain, or
Table 3 Medication, virological, and immunological response to HIV between AS and RA
AS
(n Z 18)
RA
(n Z 6)
p
HAART medications
NNRTI usage 12 (66.7) 5 (83.3) 0.629
PI usage 6 (33.3) 2 (33.3) 0.999
Diagnosis of autoimmune arthritis before using HAART 9 (50) 1 (16.7) 0.489
Time to development of autoimmune arthritis after
taking HAART, mo
13 (1e46) 67 (8e144) 0.160
CD4 T lymphocyte count
At the diagnosis of HIV 205 (39e163) [N Z 17] 144 (42e507) [N Z 4] 0.622
At the start of HAART 186 (2e456) 186.5 (11e507) 0.764
12 mo after initiating HAART 360 (0e705) [N Z 15] 437.5 (68e745) 0.726
Interval change 12 mo after initiation of HAART 175 ((14)e578) [N Z 15] 168 (57e358) 0.668
CD8 T lymphocyte count
At the diagnosis of HIV 754 (379e1354) [N Z 13] 1333 (569e2392) [N Z 5] 0.610
At the start of HAART 754 (189e1486) [N Z 17] 1282 (666e3150) 0.086
12 mo after initiating HAART 902 (18e1602) [N Z 15] 1080 (619e1944) 0.436
Interval change 12 mo after initiation of HAART 90 ((651)e943)) [N Z 11] 100.5 ((1829)e287) 0.102
Plasma HIV RNA load before the initiation of HAART,
log10 copies/mL
5.27 (4.13e6.75) 5.69 (4.94e6.18) [N Z 5] 0.146
Achieve undetectable plasma HIV RNA load 12 mo after
the initiation of HAART
12 (80) [N Z 15] 5 (83.3) 0.456
Data represent the median value (total range) for continuous variables and the number of cases (%) for categorical variables. N indicates
the number of patients being tested.
HAART Z highly active antiretroviral therapy; NNRTI Z non-nucleotide reverse transcriptase inhibitor; NSAIDs Z nonsteroidal anti-
inflammatory drugs; PI Z protease inhibitor.
Table 4 Rheumatologic treatment outcomes of AS and RA
AS
(n Z 18)
RA
(n Z 6)
p
Antirheumatic medications
Sulfasalazine 10 (55.6) 4 (66.7) 0.999
Plaquenil 2 (11.1) 3 (50) 0.079
Methotrexate 2 (11.1) 3 (50) 0.079
134 J.-J. Yang et al.hand joint pain. As the CD4þ T lymphocyte counts
increased, low back pain or stiffness gradually occurred in
all of the nine AS patients, and knee pain or hand joints
pain developed in all of the five RA patients. The diagnosis
of AS was made by the presenting symptoms, positive tests
of HLA-B27, and radiography of the lumbosacral spine and
pelvis several weeks to months after the onset of symp-
toms. Three of the nine AS patients developed extra-
articular manifestations with uveitis, and one of them
developed ulcerative colitis. The diagnosis of RA was made
by the clinical symptoms, radiographic evidence of bony
erosions, and serology markers for elevated rheumatoid
factor, anticitrullinated protein antibody, or CRP. None of
them had extra-articular presentations.
The clinical responses to rheumatological disease are
shown in Table 3. The AS group had a higher proportion of
achieving good symptomatic control at a 1-year follow-up
period (77.8% vs. 50%, p Z 0.307), while the RA group
had a greater need for the use of Plaquenil and metho-
trexate with a borderline significance (11.1% vs. 50%,
p Z 0.0785) (Table 4).Steroid 0 (0) 1 (20) 0.215
NSAIDs 15 (83.3) 6 (100) 0.546
Adalimumab 0 (0) 1 (16.7) 0.250
Good symptomatic control
at 12-mo follow-up
14 (77.8) 3 (50) 0.307
Data represent the number of cases (%) for categorical vari-
ables.
NSAIDs Z nonsteroidal anti-inflammatory drugs.Discussion
In this study of autoimmune arthritis among HIV-infected
Taiwanese patients who sought HIV care at a referral hos-
pital, it is estimated 0.49% of the patients had AS, which
was similar to the prevalence (0.19w0.54%) reported in the
general Taiwanese population. However, it is estimated
0.16% of the patients had RA, which was lower than thegeneral Taiwanese population reported (0.26w0.93%). 2 RA
was much more prevalent among the female population,
and thus our study population may have had a lower prev-
alence due to the predominantly male composition.
Although immune reconstitution with HAART may precipi-
tate development of autoimmune arthritis in patients at
risk, our research failed to demonstrate the increasing
prevalence before and after the HAART era.
Although the rate of RA is lower among HIV-infected
patients as compared with the general population, we
might have underestimated the incidence because of the
Autoimmune arthritis and HIV infection 135younger median age than the general population. An older
onset age of RA had been found to be related to higher
activation status of peripheral blood CD4þ T lymphocyte
and disease activity.15 In this study, the age at the diagnosis
of RA is significant higher than that of AS. Whether longer
survival and progressive increases of CD4 count with pro-
longed courses of combination antiretroviral therapy may
increase the incidence of AS, warrants further study.
Previous studies by Massabki and colleagues have sug-
gested that HIV infection was associated with an increased
incidence of presence of autoantibodies.16 In the era of
HAART, several different autoimmune diseases such as SLE,
Graves’ disease, and autoimmune hepatitis, have been
observed to occur during the course of combination antire-
troviral therapy.11,17,18 Some autoimmune phenomena may
be considered as one manifestation of immune reconstitu-
tion inflammatory syndrome.12,19 However, AS related to
immune reconstitution inflammatory syndrome was rarely
reported before. Most of our patients carried the HLA-B27
allele, which has been known to be a predisposing factor to
developing AS.20 As the immune reconstitution occurs with
combination antiretroviral therapy, some HIV-infected pa-
tients with autoimmune diathesis may develop autoimmune
disease, such as the HLA-B27-positive patients in our study.
Reiter’s syndrome was found in 0.4w10% of the HIV-
infected subjects, most of whom had asymmetric oligoar-
thritis,21 comparedwith 0.0035% in the general population.22
It may overlap with AS with the presentations of sacroileitis
and carrying HLA-B27 allele.23 In our study, three of the 18 AS
patients also matched the diagnosis of Reiter’s syndrome, a
kind of reactive arthritis. All the clinical presentations of
Reiter’s syndrome may be because of the presentations of
HIV-related arthritis.
The treatment response to antirheumatic agents for AS
and RA with good symptomatic control was estimated as
30w40% on the basis of the previous studies.24e26 However,
the treatment responses in the AS and RA patients of our
study were 77.8% and 50%, respectively, with a better rate
of symptomatic control. The better control for autoimmune
arthritis may result from the relative immune deficiency
state of the HIV-infected patients.
The major limitations of our study included low case
numbers of autoimmune arthritis and retrospective
method. Therefore, several laboratory data, such as anti-
nuclear antibody, antineutrophil cytoplasmic antibody, C3,
C4, and other autoantibodies were missed or incomplete. A
large longer observation is mandatory for this issue. Owing
to the lack of baseline CD4þ/CD8þ T lymphocyte counts at
the diagnosis of AS or RA in these eight patients who had
autoimmune arthritis before initiating HAART, it was diffi-
cult to evaluate the changes in CD4þ/CD8þ T lymphocyte
counts and their effect on the disease severity of AS or RA.
Owing to the unknown percentage of HIV-infected patients
that were lost to follow-up, we may have underestimated
the incidence of autoimmune arthritis among the study
population, although the percentage of HIV-infected pa-
tients lost to follow-up is quite low (<5%) at NTUH.
In conclusion, autoimmune arthritis remains a rare
complication among the HIV-infected patients receiving
HAART. The virological and immunological responses are
good in HIV-infected patients with autoimmune arthritis,
who are receiving HAART. The clinical manifestations areno different from those in the general population, but the
treatment responses to antirheumatic medications seemed
to be better than those in the general population.Conflicts of interest
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